Primary stroke prevention in nonvalvular atrial fibrillation: Implementing the clinical trial findings

Annals of Pharmacotherapy

Volumn 31, Issue 10, 1997, Pages 1187-1196

  Howard, Patricia A ^a   Duncan, Pamela W ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Arrhythmias; Aspirin; Atrial fibrillation; Prophylaxis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

COST EFFECTIVENESS ANALYSIS; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0030963777     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101012     Document Type: Review

References (42)

1. Feinberg WM, Blackshear JL, Laupacia A. Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995;155: 469-73.
2. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas (editorial). Stroke 1988;19:937-41.
3. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994;154:1443-8.
4. Gresham GE, Duncan PW, Stason WP, Adams HP, Adelman AM, Alexander DN, et al. Poststroke rehabilitation. Clinical Practice Guideline, No. 16, AHCPR Publication No. 95-0662. Rockville, MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research, May 1995.
5. Dobkin B. The economic impact of stroke. Neurology 1995;45(suppl 1): S6-S9.
6. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
7. Petersen P, Godfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagan AFASAK Study. Lancet 1989;1:175-9.
8. The Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation study: final results. Circulation 1991; 84:527-39.
9. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
10. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al., for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327: 1406-12.
11. The Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994;343:687-91.
12. The Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-8.
13. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
14. Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med 1992;152:278-82.
15. Antiplatelet Trialist's Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, MI and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
16. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology 1993;43:32-6.
17. Miller VT, Pearce LA, Feinberg WM, Rothrock JF, Anderson DC, Hart RG. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Neurology 1996;46:238-40.
18. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during anti-thrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-16.
19. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
20. Connolly SJ, for the Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation II study (letter). Lancet 1994;343:1509.
21. Ansell JE. Imprecision of prothrombin time monitoring of oral anticoagulation. Am J Clin Pathol 1992;98:237-9.
22. Morse EE, Panek S, Pisciotto P, Kiraly T, Bona R, Vose K, et al. Re-emergence of the international normalized ratio for the standardization of prothrombin time. Ann Clin Lab Sci 1993;23:184-8.
23. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-53.
24. Leitner DA, McCart GM, Knoell K. Evaluation of anticoagulation for chronic skilled-nursing facility residents. Consult Pharm 1994;9:880-914.
25. Lawson F, McAlister F, Ackman M, Ikuta R, Montague T. The utilization of anti-thrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital. J Am Geriatr Soc 1996;44:708-11.
26. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156:2311-6.
27. McCrory DC, Matchar DB, Samsa F, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
28. Chang HJ, Bell JR, Deroo DB, Kirk JW, Wasson JH. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med 1990; 150:81-4.
29. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991;151:1950-3.
30. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
31. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists and subspecialists about management of atrial fibrillation. Arch Intern Med 1996;156:2553-62.
32. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
33. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of stroke prevention in atrial fibrillation. Swedish national perspective. BMJ 1992;305:1457-60.
34. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
35. Cairns JA, Conolly SJ. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 1991;84:469-81.
36. Gage BF, Cardinali AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with atrial fibrillation. JAMA 1995;274:1839-45.
37. Eckman MH, Levine HJ, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest 1995;108(suppl 4):457S-70S.
38. Naglie G, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making 1992;12:239-49.
39. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332:238-48.
40. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995;108(suppl):352S-9S.
41. American College of Physicians. Guidelines for medical treatment for stroke prevention. Ann Intern Med 1994;121:54-5.
42. Stroke prevention recommendations, AHCPR Publication No. 95-0091. Rockville, MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research, September 1995.